We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

Majority of IV Infusion Errors Linked to Clinical Practice

By HospiMedica International staff writers
Posted on 20 Mar 2016
More than half of intravenous (IV) infusion medications contained errors, with majority linked to deviations in hospital policy, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA), Concord Hospital (NH, USA), and other institutions conducted a study in ten hospitals in the United States to investigate the types and frequency of IV medication errors associated with smart pumps. Data were collected using a prospective point prevalence approach to capture errors associated with 1,164 smart pump IV administrations to 478 patients, with concurrent evaluation of their potential for harm.

The results showed that of the observed infusions, 699 (60%) had one or more errors associated with their administration, but relatively few of these errors were potentially harmful. The most predominant errors were associated with violations of hospital infusion policy, and included the administration of unauthorized medications, bypassing the smart pump, wrong rate of infusion, labelling errors, and bypassing the integrated drug library.

The researchers suggested that most of these mistakes could be prevented if closed-loop systems, in which the smart pumps are automatically programed with a medication order using the patient’s electronic health record (EHR), were implemented as policy. This would necessitate that a nurse verify the information on the smart pump and accept the data, including drug name, infusion rate, volume, and concentration, before the infusion could begin. The study was published on February 23, 2016, in BMJ Quality & Safety.

“Since these errors are not directly related to the use of smart pumps, these finding suggest that smart pump technology alone cannot fully prevent errors associated with intravenous infusions,” concluded lead author Kumiko Schnock, MD, of Brigham and Women's Hospital, and colleagues. “The results of this study will be useful in developing interventions to eliminate errors in the intravenous medication administration process.”

Smart infusion pumps were developed to reduce adverse drug events and medication administration errors through built-in safety features, such as built-in drug libraries and dose error reduction systems. According to a national survey conducted by the American Society of Health-System Pharmacists (Bethesda, MD, USA), in 2012 77% of hospitals in the United States use smart pump technology.

Related Links:

Brigham and Women's Hospital
Concord Hospital
American Society of Health-System Pharmacists


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Surgical Dressing
ALLEVYN Ag+ SURGICAL

Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more